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Purpose: We aimed to ascertain the degree of association between bladder cancer and 
human papillomavirus (HPV) infection. 
Materials and Methods: We performed a meta-analysis of observational studies with 
cases and controls with publication dates up to January 2011. The PubMed electronic 
database was searched by using the key words “bladder cancer and virus.” Twenty-one 
articles were selected that met the required methodological criteria. We implemented 
an internal quality control system to verify the selected search method. We analyzed 
the pooled effect of all the studies and also analyzed the techniques used as follows: 
1) studies with DNA-based techniques, among which we found studies with polymerase 
chain reaction (PCR)-based techniques and 2) studies with non-PCR-based techniques, 
and studies with non-DNA-based techniques. 
Results: Taking into account the 21 studies that were included in the meta-analysis, 
we obtained a heterogeneity chi-squared value of Qexp=26.45 (p=0.383). The pooled odds 
ratio (OR) was 2.13 (95% confidence interval [CI], 1.54 to 2.95), which points to a sig-
nificant effect between HPV and bladder cancer. Twenty studies assessed the presence 
of DNA. The overall effect showed a significant relationship between virus presence 
and bladder cancer, with a pooled OR of 2.19 (95% CI, 1.40 to 3.43). Of the other six 
studies, four examined the virus’s capsid antigen and two detected antibodies in serum 
by Western blot. The estimated pooled OR in this group was 2.11 (95% CI, 1.27 to 3.51), 
which confirmed the relationship between the presence of virus and cancer. 
Conclusions: The pooled OR value showed a moderate relationship between viral in-
fection and bladder tumors.
Key Words: Human papillomavirus; Infection; Meta-analysis; Urinary bladder neoplasms;
Viruses
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 23 November, 2011
accepted 28 December, 2011
Corresponding Author:
Antonio Jimenez-Pacheco
Department of Urology, Santa Ana 
Hospital, Calle Párroco José Rodríguez 
n
o 65, Bloque A-1, 3
oB, Granada 
18014, Spain
TEL: +34-958154355
FAX: +34-958023084
E-mail: anjipa29@hotmail.com
INTRODUCTION
Bladder carcinoma is the most common of the malignant 
neoplasias of the urinary tract and is characterized by wide 
variability in prognosis. Carcinomas of transitional cells 
account for over 90% of bladder tumors [1]. The majority 
of patients tend to relapse, but a group of patients progress 
toward muscle-invasive disease [2]. To date, the mecha-
nisms associated with the initiation and progression of 
these tumors, along with possible risk factors, are not well 
known [3]. 
Many studies have tried to assess the carcinogenic risk 
of viruses such as human papillomavirus (HPV), only to 
find conflicting results. The papillomaviruses are a group 
of small, double-stranded DNA viruses that infect the 
stratified epithelium of the skin and mucosa [4]. Over 120 
different types of HPV have been described, only some of 
which implant their DNA into the host cell’s genome. HPVs 
have been classified as “low risk” (types 6 and 11) and “high 
risk” (types 16 and 18) on the basis of their implantation Korean J Urol 2012;53:240-247
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FIG. 1. Meta-analysis of all included 
studies.
properties and their tendencies to associate with benign 
processes or invasive carcinomas [1].
It has been shown that infection with HPV is implicated 
in the pathogenesis of several intraepithelial lesions and 
cancers, such as anal, cervical, and oral cancer [5]. 
However, the association of HPV with the development of 
tumors of the urinary tract continues to be controversial, 
given that in most cases, the evaluation of the results was 
difficult because appropriate control groups were lacking 
[4].
In relation to bladder carcinoma, until now, few studies 
have found an association between HPV infection and an 
increased risk for the development of neoplasias. This pos-
sible relationship is based on the epithelial tropism of HPV 
and the anatomical proximity of the urethra (which is con-
sidered a reservoir for the virus) and the bladder [1,6]. 
For this reason, it is open for debate whether the associa-
tion between chronic HPV infection and bladder carcinoma 
is a coincidence or whether the relationship is causal. To 
address this, our study identified and analyzed interna-
tionally published studies (published before January 
2011) that analyzed the relationship between bladder car-
cinoma and HPV and that described defined materials and 
methods. We conducted a meta-analysis of all of the results 
presented in these studies to analyze the currently avail-
able data on the relationship between this virus and blad-
der cancer. 
MATERIALS AND METHODS
We conducted a search of the PubMed database by using 
the keywords “bladder cancer and virus.” From this search, 
we identified 763 studies published before January 2011. 
We then selected a total of 22 studies [4,7-27] that had 
well-established groups of cases and controls; that were 
published in English, French, or Spanish; and that ana-
lyzed the relationship between HPV and bladder cancer. 
Of these studies, two were eliminated, in which the number 
of positive cases was zero in both studied groups (which 
would not allow for the calculation of any effect measure-
ment between virus presence and bladder cancer) [26,27]. 
Additionally, we added results associating HPV and blad-
der carcinoma that were found in a doctoral thesis [28].
We conducted an internal quality check system to verify 
the selected search method, which consisted of tracing the 
bibliography of each one of the selected studies. Using this 
method, we were able to confirm that no study was omitted. 　
Given the diversity of the studies, before the meta-analy-
sis, the studies were classified on the basis of the laboratory 
test used.
The heterogeneity of the studies was compared by using 
the Cochran chi-squared test (heterogeneity chi-squared- 
Qexp) and the consistency index (I
2). The odds ratio (OR) was 
calculated for each study with a 95% confidence interval 
(95% CI). The mean of the pooled OR was calculated by us-
ing the random effects model by the DerSimonian-Laird 
method. We considered the effect significant when the CI 
for the OR did not contain the value 1. Korean J Urol 2012;53:240-247
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FIG. 2. Funnel Plot of all included studies.
Publication bias was examined by using Begg’s and 
Egger’s tests. 
A forest plot was used to graphically represent the esti-
mated ORs of all studies, including the pooled effects. The 
analyses were conducted by using Metadisc software 
(Informer Technologies Inc.).
RESULTS
We analyzed the pooled effect of all the studies and also ana-
lyzed the techniques used as follows: 1) studies with 
DNA-based techniques, among which we found studies 
with polymerase chain reaction (PCR)-based techniques 
and studies with non-PCR- based techniques, and 2) stud-
ies with non-DNA-based techniques.
1. Pooled analysis of all studies
Taking into account the 21 studies included in the pooled 
meta-analysis, we obtained a heterogeneity chi-squared 
value of Qexp=26.45, with 25 degrees of freedom (p=0.383), 
which allowed us to confirm that the studies were suffi-
ciently homogeneous compared with each other. Additionally, 
the inconsistency index I
2 for the 21 studies had a value of 
5.7%, which confirmed that the percentage of hetero-
geneity was very low. The pooled OR was 2.13 (95% CI, 1.54 
to 2.95), which demonstrated a significant effect between 
HPV presence and bladder cancer (Fig. 1).
The result of the Begg’s test was not significant (p= 
0.508), allowing us to conclude that there were no indica-
tions of publication bias, which was confirmed graphically 
by the Funnel Plot (Fig. 2).
2. Studies that used DNA-based techniques
Table 1 lists the authors, the total numbers of cases and 
controls with the numbers of positives found in both 
groups, and the methods used. In the cases, 79.4% were 
transitional cell bladder tumors; in the controls, the sam-
ples were predominantly healthy bladder tissue (63.7%). 
PCR was used in the majority of the cases (80%). The ampli-
fied regions varied and tended to specify the detected viral 
genotype (the majority were type 16 or 18). Only three sam-
ples (15%) used frozen tissue biopsies.
The prevalence of HPV infection in the cases ranged from 
3.12 to 100%. In the controls, the prevalence ranged from 
0 to 100%.
We included a total of 20 studies that used DNA-based 
techniques for determination of infection. These studies 
met the hypothesis of homogeneity, with a Qexp=21.17 with 
19 degrees of freedom (p=0.3277) and an I
2=10.2%, which 
allowed us to assume comparability between the studies. 
The pooled effect showed a significant relationship be-
tween viral presence and bladder cancer, with a pooled OR 
of 2.19 (95% CI, 1.40 to 3.43). Fig. 3 shows the OR and 95% 
CI values for each of the studies. 
There was no evidence of publication bias by Begg’s test 
(p=1). 
1) Studies that used PCR-based techniques: The 16 stud-
ies that used PCR-based techniques also met the homoge-
neity criteria with a Qexp=16.46, with 15 degrees of freedom 
(p=0.352) and an I
2=8.9%. The pooled OR also confirmed 
a significant relationship between viral presence and blad-
der cancer, with a pooled OR of 2.40 (95% CI, 1.51 to 3.81) 
(Fig. 4). 
Begg’s test did not show evidence of publication bias for 
this subgroup (p=0.558).
2) Studies that used non-PCR-based techniques: The 
subgroup of studies that used non-PCR-based techniques 
was significantly smaller than the others, including only 
four studies. Despite the low number, this group also met 
the homogeneity hypothesis with a Qexp=2.78, with 3 de-
grees of freedom (p=0.426) and an I
2=0.0%. In this sub-
group, the pooled OR was 0.84 (95% CI, 0.21 to 3.31). Stati-
stical significance was not reached, which was probably re-
lated to the small number of studies included (Fig. 5). 
This subgroup also did not show evidence of publication 
bias by Begg’s test (p=0.734).
3. Studies that used non-DNA-based techniques
Table 2 lists the authors, the total numbers of cases and 
controls with the numbers of positives found in both 
groups, the materials used for the studies (carcinoma biop-
sies of transitional cells in 93.4% of the cases and samples 
of healthy bladder tissue in 42.5% of controls), and the 
methods used (four studies assessed the viral capsid anti-
gen, and two evaluated serum antibodies by use of Western 
blot).
The prevalence of HPV infection in these cases ranged 
from 17.3 to 88.8%. In the controls, the prevalence ranged 
from 0 to 66.6%.
Despite the fact that the subgroup of studies using 
non-DNA-based techniques was small, these six studies 
could be considered homogeneous with a value of Qexp=5.39, 
with 5 degrees of freedom (p=0.370) and a low I
2 of 7.3%. 
Although the number of studies was not very large, the esti-
mated pooled OR was statistically significant at 2.11 (95% 
CI, 1.27 to 3.51), which confirms the relationship between Korean J Urol 2012;53:240-247
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FIG. 4. Meta-analysis of studies that 
used PCR-based techniques.
FIG. 5. Meta-analysis of studies that 
used non-PCR-based techniques.
FIG. 3. Meta-analysis of the studies 
that used DNA-based techniques.Korean J Urol 2012;53:240-247
Relationship between Human Papillomavirus and Bladder Cancer 245
TABLE 2. Characteristics of studies based on viral antigen and antibody detection included in the meta-analysis
Author
No. of 
positive 
cases
Total cases
No. of 
positive 
controls
Total controls Tissue Analysis
Studied genotype 
(genome region)
Badawi et al. 
[9] (2008)
7 20 (17 TCC, 3 
SCC)
6 24 (cystitis) Serum ELISA, AC anti-capsid L1 
VHP 16 y 52
16, 52 (not 
indicated)
Gould et al. [4] 
(2010)
2 5 (TCC) 15 28 (4 healthy 
bladder, 6 cystitis, 
18 Inverted 
papilloma)
Fixed Overexpression of P16 + 
AC anti-P16
AC anti-P16
Guo et al. [15] 
(2006)
8 9 (CIS) 12 18 (13 non-tumoral 
bladder tissue, 5 
healthy bladder)
Serum Immunohistochemistry of 
EGFR + AC anti-EGFR
Ludwig et al. 
[18] (1996)
5 23 (21 TCC, 1 
SCC, 1 
Adenoc.)
2 41 (9 chronic 
cystitis, 32 
healthy bladder)
Serum Western blot Ag types 6b (L1, L2), 
16 (L2, E4, E7), 18 
(L2, E7)
Mantovani et 
al. [19] 
(1994)
27 45 (TCC) 28 121 (75 healthy 
bladder, 46 
non-neoplastic 
bladder tissue)
Serum ELISA and Western blot Ag genus
Smetana et al. 
[23] (1995)
19 110 (TCC) 0 41 (non-neoplastic 
bladder tissue)
Fixed IPO + AC anti-capsid
TCC, transitional cell carcinoma; SCC, squamous cell carcinoma; Adenoc., adenocarcinoma; IPO, immunoperoxidase; AC, antibody; 
Ag, antigen; ELISA, enzyme-linked immunosorbent assay; EGFR, immunohistochemistry for epithelial growth factor receptor; CIS, 
squamous cell carcinoma in situ.
FIG. 6. Meta-analysis of studies that 
used non-DNA-based techniques.
viral presence and cancer in this group (Fig. 6). 
This subgroup did not show evidence of publication bias 
by Begg’s test (p=0.707).
DISCUSSION
Bladder transitional cell carcinoma is one of the most com-
mon neoplasias in developed countries [10]. It is a clinical 
entity of which certain aspects are unknown, such as the 
existence of a genetic factor that determines its predis-
position, despite the existence of various involved onco-
genes, or the identity of the main risk factor involved in its 
genesis. These unknowns prevent us from implementing 
an effective prevention campaign. In this study, we eval-
uated HPV, which has been mentioned in the literature as 
a possible etiological agent of genital tumors, although its 
exact effect on bladder carcinoma is still vague, and numer-
ous hypotheses exist regarding its role in this regard.
The integration of HPV frequently occurs in the vicinity 
of known proto-oncogenes in human epithelial cells, al-
though it is still unknown whether this occurrence favors 
the progression of pre-cancerous lesions towards cancer. 
The viral circular double-stranded DNA must be broken for 
the oncogenic phenomenon of integration to take place. It 
has been shown that this breakage is specifically produced 
in the viral genome region encoding the E2 gene, which 
then loses its functional capacity. In the most oncogenic 
HPVs (types 16 and 18), the E2 gene seems to act mainly 
as a repressor of the transcription of genes E6 and E7, 
whose fundamental activities are to promote cellular pro-
liferation and transformation by producing centrosome 
amplification and chromosomal delay (i.e., lag) during mi-
tosis, which leads to chromosomal instability [10]. This ge-
nomic instability is thought to be an essential part of the 
conversion of a normal cell to a cancerous one.
The HPV E6 and E7 genes, especially in high-risk HPVs Korean J Urol 2012;53:240-247
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(types 16 and 18), acquire their transforming activities as 
a result of encoding E6 and E7 oncoproteins, which specifi-
cally interact with proteins regulating cell proliferation. It 
has been shown that oncoprotein E7 interacts with the cel-
lular protein p105 Rb, which is encoded by the retino-
blastoma gene Rb1. The interaction of the HPV E7 oncopro-
tein with the regulator protein p105-Rb presumably in-
activates p105-Rb, with similar consequences as those that 
occur in tumors encoding retinoblastoma gene alterations. 
In contrast, the association of E6 with p53 may give rise to 
an effect similar to what happens after mutation of the p53 
gene. It is thought that this constitutes one of the oncogenic 
pathways of HPV [29]. 
Some authors have reported that the sensitivity of HPV 
detection greatly depends on several technical factors, 
such as tissue fixation, DNA preparation, and amplifica-
tion conditions [19]. 
Over the years, microbiological tests used for the de-
tection of infection have changed. PCR and in situ hybrid-
ization are techniques with high sensitivities and specific-
ities for viral genome detection [1]; these techniques have 
been used most commonly in studies. This, however, 
should not detract from the value of other techniques for 
which specificities and sensitivities have been reported.
Li et al. [30] presented the outcomes of a meta-analysis 
of articles published from January 1989 until August 2010 
in which they showed an association between HPV and 
bladder cancer. The authors discussed important issues 
that were not analyzed in previous meta-analyses, such as 
the geographic variation in risk of bladder cancer with HPV 
infection; the most common HPV types identified, which 
are similar to those identified in other tumors, mainly cer-
vical tumors; and the sensitivity of detection of infection as 
a function of the method used. 
In the present meta-analysis, in addition to the techni-
ques based on DNA detection (PCR-based methods and 
non-PCR-methods) noted by Li et al. [30], we included the 
analysis of seven studies that used virus detection techni-
ques that were not based on DNA (i.e., the detection of viral 
capsid antigen and antibodies in serum by Western blot-
ting). In this case, the joint point estimate of the prevalence 
of infection through the detection of antigen or antibody 
was 32.4%.
We can observe that the association between HPV and 
bladder cancer varies with geographical location. Elevated 
percentages of HPV detection have been documented in 
bladder tumors in Southeast Asia, reaching up to a re-
ported 81% in Hong Kong [31]. Lower percentages have 
been detected in Europe and North America, not exceeding 
39% [1]. It is possible that these differences are related to 
problems in diagnostic techniques, such as not using a wide 
enough range of specific primers for PCR, or having sam-
ples containing DNA from less-common types of HPV, lead-
ing to false-negatives [1]. 
Another issue to consider is that of justifying the associa-
tion, given that the virus could be present in a lesion before 
it appears as an inductor to be acquired during sexual 
intercourse. This does not rule out that the tumor may be 
secondarily colonized as part of the mucosal microbiota [6].
In our study, the Qexp values obtained from the analysis 
of studies using non-DNA-based and DNA-based techni-
ques, viral genome PCR detection methods, and non-PCR 
detection methods showed homogeneity of data and a small 
dispersion of results. Of the 21 selected studies, we ob-
tained a pooled OR of 2.13, allowing us to conclude that 
there is a clear and moderate association between virus ex-
posure and the presence of bladder cancer.
CONCLUSIONS
As of January 2011, there were only 21 studies with both 
case and control groups that analyzed the relationship be-
tween HPV and bladder cancer. The methods used varied, 
but PCR use predominated. The studies demonstrated the 
presence of infection in the majority of cases, although an 
important dispersion was observed. The pooled OR value 
showed a moderate relationship between infection by the 
virus and the tumor. There is a lack in the literature of a 
sufficiently large number of cases and samples that are 
compared with controls and that use a combination of mi-
crobiological techniques in the same subjects and samples 
to obtain a definitive answer to this question. For this rea-
son, the relationship between the virus and this tumor 
should continue to be evaluated through pathogenic stud-
ies of the disease.
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